Faculty Opinions recommendation of Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726282237.793552147 ◽

2018 ◽

Author(s):

Richard Riedel

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

Gastrointestinal Stromal Tumours ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00075-9 ◽

2016 ◽

Vol 17 (5) ◽

pp. 632-641 ◽

Author(s):

Olivier Mir ◽

Claire Cropet ◽

Maud Toulmonde ◽

Axel Le Cesne ◽

Mathieu Molimard ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

Gastrointestinal Stromal Tumours ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30242-5 ◽

2017 ◽

Vol 18 (5) ◽

pp. 672-681a ◽

Author(s):

Jesus García-Donas ◽

Albert Font ◽

Begoña Pérez-Valderrama ◽

José Antonio Virizuela ◽

Miquel Ángel Climent ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase ◽

Advanced Urothelial Carcinoma ◽

Randomised Controlled ◽

Line Chemotherapy

Download Full-text

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70098-7 ◽

2015 ◽

Vol 16 (4) ◽

pp. 406-416 ◽

Author(s):

Akira Kawai ◽

Nobuhito Araki ◽

Hideshi Sugiura ◽

Takafumi Ueda ◽

Tsukasa Yonemoto ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

Standard Chemotherapy ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

The Lancet Rheumatology ◽

10.1016/s2665-9913(20)30341-6 ◽

2020 ◽

Vol 2 (12) ◽

pp. e764-e773 ◽

Author(s):

Alexander P J Vlaar ◽

Sanne de Bruin ◽

Matthias Busch ◽

Sjoerd A M E G Timmermans ◽

Ingeborg E van Zeggeren ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Supportive Care ◽

Controlled Trial ◽

Best Supportive Care ◽

Phase 2 ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00030-2 ◽

2021 ◽

Vol 8 (4) ◽

pp. e289-e298 ◽

Author(s):

Lu Sun ◽

Juan Wang ◽

Linlin Shao ◽

Chenglu Yuan ◽

Hongguo Zhao ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Phase 2 ◽

Phase 2 Trial ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739562946.793583755 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Phase 2 Trial ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Virus Genotype ◽

Phase 2 Trial ◽

Open Label Phase ◽

Download Full-text

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(18)30480-8 ◽

2019 ◽

Vol 19 (1) ◽

pp. 46-55 ◽

Author(s):

Jung-Kyu Lee ◽

Ji Yeon Lee ◽

Deog Kyeom Kim ◽

Ho Il Yoon ◽

Ina Jeong ◽

...

Keyword(s):

Pulmonary Tuberculosis ◽

Phase 2 ◽

Intensive Phase ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text